A naturally protective epitope of limited variability as an influenza vaccine target

Craig P. Thompson; José Lourenço; Adam A. Walters; Uri Obolski; Matthew Edmans; Duncan S. Palmer; Kreepa Kooblall; George W. Carnell; Daniel O’Connor; Thomas A. Bowden; Oliver G. Pybus; Andrew J. Pollard; Nigel J. Temperton; Teresa Lambe; Sarah C. Gilbert; Sunetra Gupta

doi:10.1038/s41467-018-06228-8

A naturally protective epitope of limited variability as an influenza vaccine target

Craig P. Thompson^*, José Lourenço, Adam A. Walters, Uri Obolski, Matthew Edmans, Duncan S. Palmer, Kreepa Kooblall, George W. Carnell, Daniel O’Connor, Thomas A. Bowden, Oliver G. Pybus, Andrew J. Pollard, Nigel J. Temperton, Teresa Lambe, Sarah C. Gilbert, Sunetra Gupta

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Current antigenic targets for influenza vaccine development are either highly immunogenic epitopes of high variability or conserved epitopes of low immunogenicity. This requires continuous update of the variable epitopes in the vaccine formulation or boosting of immunity to invariant epitopes of low natural efficacy. Here we identify a highly immunogenic epitope of limited variability in the head domain of the H1 haemagglutinin protein. We show that a cohort of young children exhibit natural immunity to a set of historical influenza strains which they could not have previously encountered and that this is partially mediated through the epitope. Furthermore, vaccinating mice with these epitope conformations can induce immunity to human H1N1 influenza strains that have circulated since 1918. The identification of epitopes of limited variability offers a mechanism by which a universal influenza vaccine can be created; these vaccines would also have the potential to protect against newly emerging influenza strains.

Original language	English
Article number	3859
Journal	Nature Communications
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41467-018-06228-8
State	Published - 1 Dec 2018
Externally published	Yes

Funding

Funders	Funder number
European Commission
Royal Society
UK Research and Innovation
Wellcome Trust	203141
European Molecular Biology Organization	203141/Z/16/Z.
Medical Research Council	MR/L009528/1, MC_PC_15029
Seventh Framework Programme	614725, 268904
European Research Council	FP7/20–2013
Horizon 2020 Framework Programme	812816

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41467-018-06228-8

Cite this

Thompson, C. P., Lourenço, J., Walters, A. A., Obolski, U., Edmans, M., Palmer, D. S., Kooblall, K., Carnell, G. W., O’Connor, D., Bowden, T. A., Pybus, O. G., Pollard, A. J., Temperton, N. J., Lambe, T., Gilbert, S. C., & Gupta, S. (2018). A naturally protective epitope of limited variability as an influenza vaccine target. Nature Communications, 9(1), Article 3859. https://doi.org/10.1038/s41467-018-06228-8

@article{572d43237cd1463d8a9303fc802345ea,

title = "A naturally protective epitope of limited variability as an influenza vaccine target",

abstract = "Current antigenic targets for influenza vaccine development are either highly immunogenic epitopes of high variability or conserved epitopes of low immunogenicity. This requires continuous update of the variable epitopes in the vaccine formulation or boosting of immunity to invariant epitopes of low natural efficacy. Here we identify a highly immunogenic epitope of limited variability in the head domain of the H1 haemagglutinin protein. We show that a cohort of young children exhibit natural immunity to a set of historical influenza strains which they could not have previously encountered and that this is partially mediated through the epitope. Furthermore, vaccinating mice with these epitope conformations can induce immunity to human H1N1 influenza strains that have circulated since 1918. The identification of epitopes of limited variability offers a mechanism by which a universal influenza vaccine can be created; these vaccines would also have the potential to protect against newly emerging influenza strains.",

author = "Thompson, {Craig P.} and Jos{\'e} Louren{\c c}o and Walters, {Adam A.} and Uri Obolski and Matthew Edmans and Palmer, {Duncan S.} and Kreepa Kooblall and Carnell, {George W.} and Daniel O{\textquoteright}Connor and Bowden, {Thomas A.} and Pybus, {Oliver G.} and Pollard, {Andrew J.} and Temperton, {Nigel J.} and Teresa Lambe and Gilbert, {Sarah C.} and Sunetra Gupta",

note = "Publisher Copyright: {\textcopyright} 2018, The Author(s).",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41467-018-06228-8",

language = "אנגלית",

volume = "9",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

Thompson, CP, Lourenço, J, Walters, AA, Obolski, U, Edmans, M, Palmer, DS, Kooblall, K, Carnell, GW, O’Connor, D, Bowden, TA, Pybus, OG, Pollard, AJ, Temperton, NJ, Lambe, T, Gilbert, SC & Gupta, S 2018, 'A naturally protective epitope of limited variability as an influenza vaccine target', Nature Communications, vol. 9, no. 1, 3859. https://doi.org/10.1038/s41467-018-06228-8

TY - JOUR

T1 - A naturally protective epitope of limited variability as an influenza vaccine target

AU - Thompson, Craig P.

AU - Lourenço, José

AU - Walters, Adam A.

AU - Obolski, Uri

AU - Edmans, Matthew

AU - Palmer, Duncan S.

AU - Kooblall, Kreepa

AU - Carnell, George W.

AU - O’Connor, Daniel

AU - Bowden, Thomas A.

AU - Pybus, Oliver G.

AU - Pollard, Andrew J.

AU - Temperton, Nigel J.

AU - Lambe, Teresa

AU - Gilbert, Sarah C.

AU - Gupta, Sunetra

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Current antigenic targets for influenza vaccine development are either highly immunogenic epitopes of high variability or conserved epitopes of low immunogenicity. This requires continuous update of the variable epitopes in the vaccine formulation or boosting of immunity to invariant epitopes of low natural efficacy. Here we identify a highly immunogenic epitope of limited variability in the head domain of the H1 haemagglutinin protein. We show that a cohort of young children exhibit natural immunity to a set of historical influenza strains which they could not have previously encountered and that this is partially mediated through the epitope. Furthermore, vaccinating mice with these epitope conformations can induce immunity to human H1N1 influenza strains that have circulated since 1918. The identification of epitopes of limited variability offers a mechanism by which a universal influenza vaccine can be created; these vaccines would also have the potential to protect against newly emerging influenza strains.

AB - Current antigenic targets for influenza vaccine development are either highly immunogenic epitopes of high variability or conserved epitopes of low immunogenicity. This requires continuous update of the variable epitopes in the vaccine formulation or boosting of immunity to invariant epitopes of low natural efficacy. Here we identify a highly immunogenic epitope of limited variability in the head domain of the H1 haemagglutinin protein. We show that a cohort of young children exhibit natural immunity to a set of historical influenza strains which they could not have previously encountered and that this is partially mediated through the epitope. Furthermore, vaccinating mice with these epitope conformations can induce immunity to human H1N1 influenza strains that have circulated since 1918. The identification of epitopes of limited variability offers a mechanism by which a universal influenza vaccine can be created; these vaccines would also have the potential to protect against newly emerging influenza strains.

UR - http://www.scopus.com/inward/record.url?scp=85053713871&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-06228-8

DO - 10.1038/s41467-018-06228-8

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:85053713871

SN - 2041-1723

VL - 9

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 3859

ER -